Unique ID issued by UMIN | UMIN000004899 |
---|---|
Receipt number | R000005835 |
Scientific Title | Evaluation of Usefulness and Safety of Support Food for Recovery of Eating Function iEat in Patients with Gastrointestinal Cancer Stenosis. |
Date of disclosure of the study information | 2011/01/19 |
Last modified on | 2014/12/01 14:13:35 |
Evaluation of Usefulness and Safety of Support Food for Recovery of Eating Function iEat in Patients with Gastrointestinal Cancer Stenosis.
Evaluation of Usefulness and Safety of Support Food for Recovery of Eating Function iEat in Patients with Gastrointestinal Cancer Stenosis.
Evaluation of Usefulness and Safety of Support Food for Recovery of Eating Function iEat in Patients with Gastrointestinal Cancer Stenosis.
Evaluation of Usefulness and Safety of Support Food for Recovery of Eating Function iEat in Patients with Gastrointestinal Cancer Stenosis.
Japan |
Malignancy
Gastrointestinal surgery |
Malignancy
NO
To determine whether iEat is safety in patients for whom gastrointestinal cancer stenosis is indicated. Furthermore, to evaluate satisfaction of iEat compare to the regular hospital diet by feeding rate and questionnaire.
Safety,Efficacy
To evaluate safety (digestive symptoms) during the trial (in principal 7 days). Outcomes are abdominal pain, diarrhea, abdominal fullness, nausea, vomiting. Outcomes will be graded according to Common Terminology Criteria for Adverse Events v.4.0 JCOG version (Abbr. CTCAE v4.0 JCOG) [Equiv. CTCAE v4.02/MedRA/J v12.1 Published February 1, 2010]
Feeding rate
Questionnaire about satisfaction
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Treatment
Food |
Study period will be seven consecutive days. Five consecutive days of iEat and before-and-after one day of regular diet. iEat will be provided only lunch every day. Breakfast and dinner will be regular hospital diet (rice porridge or liquid diet).
20 | years-old | <= |
Not applicable |
Male and Female
1)Patients who have given voluntary written informed consent
2)Patients aged 20 years and older at the time of informed consent
3)Male or female patients
4)Do not consider presence or absence of gastrointestinal stent placement
5)Do not consider presence or absence of chemotherapy
1)Patients who cannot be communicated with the investigator, etc. due to disturbance of consciousness and dementia, etc.
2)Patients with food allergy
3)Patients with concomitantly-used tube feeding
4)Patients judged to be inappropriate for the study by the investigator
10
1st name | |
Middle name | |
Last name | IIJIMA, Shohei |
Minoh City Hospital
Department of Surgery
5-7-1, Kayano, Minoh, Osaka 562-8562, JAPAN
1st name | |
Middle name | |
Last name |
Minoh City Hospital
Department of Surgery
5-7-1, Kayano, Minoo, Osaka 562-8562, JAPAN
Minoh City Hospital
EN Otsuka Pharmaceutical Co., Ltd.
Profit organization
NO
2011 | Year | 01 | Month | 19 | Day |
Unpublished
Completed
2010 | Year | 11 | Month | 17 | Day |
2011 | Year | 01 | Month | 01 | Day |
2013 | Year | 03 | Month | 31 | Day |
2013 | Year | 03 | Month | 31 | Day |
2013 | Year | 03 | Month | 31 | Day |
2013 | Year | 04 | Month | 30 | Day |
2011 | Year | 01 | Month | 19 | Day |
2014 | Year | 12 | Month | 01 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000005835